Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.

Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y

Journal of clinical oncology : official journal of the American Society of Clinical Oncology5 Nov 2012Cited by 92 (Europe PMC)

PMID23129737DOI10.1200/jco.2012.42.8185PepBankPUB-23129737

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with lymphoma, ovarian failure at 1 year was similar with triptorelin plus norethisterone and norethisterone alone (20% versus 19%).
In plain wordsIn patients with lymphoma, ovarian failure at 1 year was similar with triptorelin plus norethisterone and norethisterone alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePremature ovarian failure at one year
Study
n = 84
Comparator
Norethisterone alone with chemotherapy
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Premature ovarian failure rate
20%
Triptorelin plus norethisterone
Premature ovarian failure rate
19%
Norethisterone alone
Source sentences
Summary
After 1 year, 20% and 19% of patients in the GnRHa and control groups, respectively, exhibited POF (P = 1.00).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up.
Summary · context
Eighty-four of 129 randomly assigned patients completed the 1-year follow-up.
Summary · context
Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy.
Report a problemFND-2312973703
02HumanRandomized controlled trialEfficacy outcome
In patients with lymphoma, AMH was higher with triptorelin plus norethisterone than norethisterone alone (1.4 versus 0.5 ng/mL).
In plain wordsIn patients with lymphoma, AMH was higher with triptorelin plus norethisterone than norethisterone alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAnti-Müllerian hormone
Study
n = 84
Comparator
Norethisterone alone with chemotherapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
AMH
1.4 ng/mL
Triptorelin plus norethisterone
AMH
0.5 ng/mL
Norethisterone alone
Source sentences
Summary
More than half of patients in each group completely restored their ovarian function (FSH < 10 IU/L), but the anti-Müllerian hormone values were higher in the GnRHa group than in the control group (1.4 ± 0.35 v 0.5 ± 0.15 ng/mL, respectively; P = .040).
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-four of 129 randomly assigned patients completed the 1-year follow-up.
Summary · context
Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy.
Report a problemFND-2312973705
03HumanRandomized controlled trialEfficacy outcome
In patients with lymphoma, adding triptorelin to norethisterone lowered mean FSH during chemotherapy compared with norethisterone alone.
In plain wordsIn patients with lymphoma, adding triptorelin to norethisterone lowered FSH during chemotherapy compared with norethisterone alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFSH during chemotherapy
Study
n: not reported in source
Comparator
Norethisterone alone with chemotherapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
The mean FSH values were higher in the control group than in the GnRHa group during chemotherapy; however, this difference was no longer observed after 6 months of follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy.
Report a problemFND-2312973701
04HumanRandomized controlled trialEfficacy outcome
In patients with lymphoma, FSH no longer differed after 6 months between triptorelin plus norethisterone and norethisterone alone.
In plain wordsIn patients with lymphoma, FSH did not differ after 6 months between triptorelin plus norethisterone and norethisterone alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFSH after six months
Study
n: not reported in source
Comparator
Norethisterone alone with chemotherapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
The mean FSH values were higher in the control group than in the GnRHa group during chemotherapy; however, this difference was no longer observed after 6 months of follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy.
Report a problemFND-2312973702
05HumanRandomized controlled trialSafety outcome
In patients with lymphoma, adverse events were similar with triptorelin plus norethisterone and norethisterone alone, except metrorrhagia.
In plain wordsIn patients with lymphoma, adverse events were similar with triptorelin plus norethisterone and norethisterone alone, except metrorrhagia.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeAdverse events
Study
n: not reported in source
Comparator
Norethisterone alone with chemotherapy
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
The occurrence of adverse events was similar in both groups with the exception of metrorrhagia, which was more frequently observed in the control group than the GnRHa group (38.4% v 15.6%, respectively; P = .024).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy.
Report a problemFND-2312973706
06HumanRandomized controlled trialSafety outcome
In patients with lymphoma, metrorrhagia was less frequent with triptorelin plus norethisterone than norethisterone alone (15.6% versus 38.4%).
In plain wordsIn patients with lymphoma, metrorrhagia was less frequent with triptorelin plus norethisterone than norethisterone alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseMetrorrhagia
Study
n: not reported in source
Comparator
Norethisterone alone with chemotherapy
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Metrorrhagia frequency
15.6%
Triptorelin plus norethisterone
Metrorrhagia frequency
38.4%
Norethisterone alone
Source sentences
Summary
The occurrence of adverse events was similar in both groups with the exception of metrorrhagia, which was more frequently observed in the control group than the GnRHa group (38.4% v 15.6%, respectively; P = .024).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy.
Report a problemFND-2312973707

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In patients with lymphoma, more than half restored ovarian function in each group, including triptorelin plus norethisterone.
In plain wordsIn patients with lymphoma, more than half restored ovarian function in each group, including triptorelin plus norethisterone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableRestoration of ovarian function
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
More than half of patients in each group completely restored their ovarian function (FSH < 10 IU/L),
2 context sentences(design, population, supporting numbers)
Summary · context
Eighty-four of 129 randomly assigned patients completed the 1-year follow-up.
Summary · context
Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2312973704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3NCT01160315

Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure

Erasme University Hospitaln = 118Jul 2002 to Oct 2015

Fertility Preservation · Alkylating Agents · Lymphoma

Trial page ClinicalTrials.govUpdated 30 Oct 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.